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Abstract 
 
Flubendazole (FLBZ) is a broad-spectrum benzimidazole anthelmintic compound used in pigs, 
poultry and humans. Its potential for parasite control in ruminant species is under 
investigation. The objective of the work described here was to identify the main enzymatic 
pathways involved in the hepatic and extra-hepatic biotransformation of FLBZ in sheep. 
Microsomal and cytosolic fractions obtained from sheep liver and duodenal mucosa 
metabolised FLBZ into a reduced FLBZ metabolite (red- FLBZ). The keto-reduction of FLBZ 
led to the prevalent (~98%) stereospecific formation of one enantiomeric form of red-FLBZ. 
The amounts of red-FLBZ formed in liver subcellular fractions were 3 to 4-fold higher 
(P<0.05) compared to those observed in duodenal subcellular fractions. This observation 
correlates with the higher (P<0.05) carbonyl-reductase (CBR) activities measured in the liver 
compared to the duodenal mucosa. No metabolic conversion was observed following FLBZ 
or red-FLBZ incubation with sheep ruminal fluid. Sheep liver microsomes failed to convert 
red-FLBZ into FLBZ. However, this metabolic reaction occurred in liver microsomes 
prepared from phenobarbital-induced rats, which may indicate a cytochrome P450-mediated 
oxidation of red-FLBZ. A NADPH-dependent CBR is proposed as the main enzymatic 
system involved in the keto-reduction of FLBZ in sheep. CBR substrates such as menadione 
and mebendazole (a non fluoride analogue of FLBZ), inhibited this liver microsomal 
enzymatic reaction, which may confirm the involvement of a CBR enzyme in FLBZ 
metabolism in sheep. This research is a further contribution to the understanding of the 
metabolic fate of a promissory alternative compound for antiparasitic control in ruminant 
species.  
Keywords: flubendazole; anthelmintics; biotransformation; microsomes; carbonyl reductase; 
sheep.  
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1. Introduction 
 
Livestock animals are continuously exposed to a variety of xenobiotic agents (i.e.: veterinary 
drugs, feed-additives, pesticides, pollutants, etc.) during their production cycles. These 
compounds are likely to be metabolised by different enzymatic systems from both hepatic and 
extra-hepatic tissues. The metabolic activity of different phase 1 and phase 2 xenobiotic 
metabolising enzymes play a major role in determining the persistence of therapeutically used 
drugs in target species, which may additionally impose a risk to the consumers as a 
consequence of the permanence of drug residue levels in edible tissues. Metabolic interactions 
with such enzymatic systems may drastically affect the disposition kinetics of different drugs 
used in animal production, which will have a relevant impact on the pattern of 
drug/metabolites residues in tissues, a major concern for public health and consumer's safety. 
 
Xenobiotic biotransformation takes place predominantly in the liver, although metabolic 
activity is apparent in extra-hepatic tissues, such as the gastrointestinal tract. In addition to its 
primary role in the absorption of nutrients and water, the intestine is a major route of entry 
into the body for many xenobiotics. The intestinal mucosa constitutes an absorptive barrier in 
the uptake of toxic compounds and/or orally administered therapeutically used drugs. In 
addition, the gut mucosa has the ability to metabolise a great number of xenobiotic 
compounds by numerous pathways involving both phase 1 and phase 2 reactions [1].  
 
Ruminants nutritional physiology has been widely studied and a great number of 
investigations focused on the metabolic activity of the microflora present in the rumen (the 
largest forestomach cavity in these species). However, most research has mainly examined the 
fermentation of dietary components and much less attention has been given to the 
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biotransformation of compounds without nutritional relevance [2]. Ruminant animals have a 
symbiotic relationship with their ruminal microflora (bacteria, protozoa and fungi) which 
allows them to digest fibrous plant materials [3]. Anaerobic conditions predominate in the 
ruminal environment and substrates are only partially oxidised. Therefore, while oxidative 
metabolism predominates in the liver and in the intestinal mucosa, reductive and hydrolytic 
reactions are of primary importance in the rumen. For instance, ruminal microorganisms are 
very active in reductive reactions of foreign compounds, particularly those containing -nitro 
[4, 5] and -sulphoxide [6, 7] groups. Thus, drug metabolic processes taking place in the rumen 
are particularly important in ruminant therapeutics.  
 
Flubendazole (FLBZ), methyl ester of [5-(4-fluorobenzoyl)-1H-benzimidalzol-2-yl]carbamic 
acid, is a broad-spectrum benzimidazole (BZD) methylcarbamate anthelmintic available for 
use in human and veterinary medicine. FLBZ is a fluoride derivative of mebendazole (MBZ) 
and is widely used for parasite control in pigs, chicken, turkeys and game birds. Unlike other 
commonly used BZD anthelmintics such as albendazole (aliphatic substitution at position -5) 
and fenbendazole (aromatic substitution at position -5), MBZ and FLBZ do not contain a 
sulphur atom at the same position. Instead, a ketone group is present in both anthelmintic 
molecules, which may have implications in their metabolic pattern within the host. While 
sulphur-containing BZDs are sequentially oxidised to their sulphoxide and sulphone 
metabolites by both flavin-monooxygenase (FMO) and cytochrome P450 (P450) systems in 
the liver [8 - 12], carbonyl reductases (CBRs) are thought as the main enzymatic system 
involved in the metabolism of MBZ and FLBZ [13, 14].  
 
Previous work carried out in our laboratory described an integrated pharmacological assessment 
of the disposition kinetics and the liver microsomal biotransformation of FLBZ in sheep, as well 
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as it’s ex vivo diffusion through the tegument of the cestode parasite Moniezia benedeni [15]. 
The parent drug and its reduced (red-FLBZ) and hydrolyzed (h-FLBZ) metabolites were found 
in the bloodstream of FLBZ-treated sheep. In addition, sheep liver microsomes were able to 
metabolise FLBZ into red-FLBZ. The proposed pattern for FLBZ biotransformation is shown 
in Figure 1. Considering the potential of FLBZ as a broad-spectrum anthelmintic for use in 
ruminant species, the work reported here was addressed to gain further insight into the 
identification of the specific metabolic pathways involved in FLBZ metabolism in the host. 
The involvement of the ruminal microflora in either the reduction or hydrolysis of FLBZ was 
also assessed. Overall, this research contributes to characterise the patterns of hepatic and 
extra-hepatic biotransformation of this anthelmintic drug in sheep, which may be considered 
critical to optimise its pharmacological activity.  
 
 
2. Material and methods 
 
2.1. Reagents: Reference standards (99.5 % pure) of FLBZ and its reduced (red-FLBZ) and 
hydrolyzed (h-FLBZ) metabolites were kindly provided by Janssen Animal Health (Beerse, 
Belgium). Stock solutions (2.5 mM) of each molecule were prepared in methanol (Baker Inc., 
Phillipsburg, USA). Albendazole sulphoxide (ABZSO), used as internal standard,
 
was provided 
by Schering Plough (Kenilworth, New Jersey, USA). Phenobarbital (PB) was purchased from 
J´anvier (Buenos Aires, Argentina). Mebendazole (MBZ), quercetin (QRC), menadione (MEN), 
warfarin (WRF), piperonyl butoxide (PBO), chlorpheniramine maleate salt, oleandomycin 
triacetate, aminopyrine, nicotinamide adenine dinucleotide phosphate (NADP+) and trypsin 
inhibitor (Type II-S: soybean) were purchased from Sigma-Aldrich Chemical Company (St. 
Louis, USA). Glucose-6-phosphate and glucose-6-phosphate dehydrogenase were purchased 
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 6 
from Roche Applied Science (Buenos Aires, Argentina). Erythromycin was obtained from the 
local market (Parafarm, Buenos Aires, Argentina). The solvents used for the chemical 
extraction and chromatographic analysis were HPLC grade (Baker Inc., Phillipsburg, USA). 
Buffer salts (KCl, NaHCO3, Na2HPO4, NaH2PO4, K2HPO4, KH2PO4 and CH3COONH4) were 
purchased from Baker Inc. (Phillipsburg, USA).  
 
2.2. Animals: Five (5) healthy Corriedale x Merino cross-breed rams were sacrificed to obtain 
samples of liver parenchyma and duodenal mucosa for preparation of the microsomal and 
cytosolic fractions. Ruminal fluid was collected from three (3) animals. Sheep were fed with 
high quality lucerne hay and water ad libitum.  
 
Eight (8) female rats (280-310 g) were randomly allocated in two experimental groups 
(control and PB-induced) of four (4) animals each other. Both control and PB-treated rats 
received food and water ad libitum. Drinking water in PB-treated animals was supplied with 
the drug (1 mg/mL) during 1 week. The average dose of PB administered (68 mg/kg of body 
weight) was estimated by recording the quantity of water ingested per day. Animal procedures 
and management protocols were carried out according to the Animal Welfare Policy 
(Academic Council Resolution 087/02) of the Faculty of Veterinary Medicine, Universidad 
Nacional del Centro de la Provincia de Buenos Aires (UNCPBA), Tandil, Argentina 
(http://www.vet.unicen.edu.ar). Animals were stunned and exsanguinated immediately in 
agreement with these institutional and internationally accepted animal welfare guidelines [16].  
 
2.3. Preparation of subcellular fractions: These procedures were adapted from the 
methodology described by Nebbia et al., (2003) [17]. After sacrifice, the abdomen was 
opened and the liver (sheep and rats) was removed. Samples were rinsed with ice-cold KCl 
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1.15 % and then stored in aluminium foils, chilled in ice and transported to the laboratory. All 
subsequent operations were performed between 0 and 4 °C. Liver samples (8 g) from each 
experimental animal were cut into small pieces with scissors.   
 
Segments (40-50 cm) of sheep duodenum were also obtained. The gut content was discarded 
and the segment was opened through a longitudinal incision. Then, the mucosa was washed 
with ice-cold KCl 1.15 %, blotted dry and thereafter scraped using a microscope glass slide. 
All samples were transported to the laboratory in iced cold homogenization buffer (0.1 M 
potassium phosphate, pH 7.4, 0.1 M Tris acetate, 0.1M KCl, 1mM EDTA, 18 µM butylated 
hydroxytoluene, and 1 mg/mL trypsin inhibitor) at 4 °C.  
 
Microsomal and cytosolic fractions from both liver and intestinal tissues were isolated by 
differential ultracentrifugation. Tissue samples were weighted and homogenised using a 
Potter-Elvenjem tool (four to six passes) with two volumes of ice-cold homogenisation buffer. 
Homogenates were filtered through a hydrophilic gauze, centrifuged at 10 000 g for 20 min 
and the resulting supernatant at 100 000 g for 65 min. Aliquots of supernatants (cytosolic 
fractions) were frozen in liquid nitrogen an stored at –70 °C. Pellets (microsomal preparations 
from both tissues) were suspended in a 0.1 M potassium phosphate buffer (containing 0.1 mM 
of EDTA and 20 % of glycerol), frozen in liquid nitrogen and stored at -70 °C until used for 
incubation assays. An aliquot of each subcellular fraction was used to determine protein 
content using bovine serum albumin as a control standard [18].  
 
2.4. Determination of carbonyl reductase (CBR) activities: CBR activities were measured 
in liver and duodenal subcellular fractions by incubating MEN as a substrate and recording 
the consumption (oxidation) of NADPH at 37 °C in a spectrofluorophotometer (Shimadzu 
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Corporation, Kyoto, Japan, RF-5301PC) at an excitation wavelength of 380 nm and a 
maximum of emission wavelength of 460 nm. Briefly, each subcellular fraction was pre-
incubated at 37 °C over 5 min and then the NADPH disappearance was monitored for 5 
minutes in presence of MEN at an acquisition rate of 1 reading/20 seconds. Typical reaction 
mixtures performed for determination of the kinetic parameters (Km and Vmax) contained: 250 
µM NADPH, 0.75 mg of liver microsomal protein, 0.1 M potassium phosphate buffer (pH 
7.4) and variable concentrations of MEN (62.5 to 1000 µM) in a final volume of 3 mL. 
Comparative CBR activities in cytosolic and microsomal fractions from liver and duodenal 
mucosa were performed using 500 µM MEN. Inhibition studies of CBR activity in liver 
microsomes were carried out by incubation of 125 µM MEN in presence of quercetin (20 
µM). All metabolic reactions started with the addition of the specific substrate.  
 
2.5. Enzyme assays in liver and duodenal microsomal and cytosolic fractions: FLBZ keto-
reductase enzymatic biotransformation was assessed in each subcellular fraction by the 
amount of red-FLBZ formed in the presence of a NADPH generating system. Incubations 
using red-FLBZ as substrate were also carried out in liver microsomes. A typical reaction 
mixture contained (in a final volume of 0.5 mL): phosphate buffer 0.1 M (pH 7.4), 0.5 mg of 
microsomal or cytosolic protein diluted in 50 µL of the same buffer, NADPH-generating 
system (NADP+ 0.32 mM, glucose-6-phosphate 6.4 mM, MgCl2 5 mM, EDTA 0.8 mM and 
1.25 U of glucose-6-phosphate dehydrogenase in phosphate buffer) and 40 µM of FLBZ or red-
FLBZ dissolved in 10 µL methanol. All incubation mixtures were allowed to equilibrate (5 
min at 37 °C) and the reaction started with the addition of the NADPH-generating system. 
Incubations (15 or 30 min at 37 °C) were carried out in polypropylene vials in an oscillating 
water bath under aerobic conditions.  
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The biotransformation of FLBZ in sheep liver microsomes was also studied in the presence of 
MEN and WRF (known CBR substrates), mebendazole (MBZ, a non fluoride analogue of 
FLBZ) and piperonyl butoxide (PBO, known as a P450 inhibitor). Microsomal preparations 
containing MEN (40, 80 and 160 µM), WAR (40, 80 and 160 µM), MBZ (40 µM) or PBO 
(100 and 200 µM) were pre-incubated (5 min at 37 ºC) in the presence of FLBZ (40 µM). 
Then, each reaction was initiated by the addition of the NADPH-generating system. MEN and 
WRF were dissolved in 0.1 M phosphate buffer; while MBZ and PBO were dissolved in 10 
µL of methanol (parallel control tubes contained the same volume of the solvent).  
 
Blank samples, containing all components of the reaction mixture except the NADPH-
generating system, were also incubated under the same conditions. These incubations were 
used as controls for possible non enzymatic drug conversion. All reactions were stopped by 
the addition of 0.2 mL of acetonitrile and stored at -20 °C until analysis. 
  
2.6. Cytochrome P450-mediated demethylase activities in rat liver microsomes: The 
response to PB treatment was assessed by the quantification of P450-dependent N-
demethylase activities towards several substrates, which in humans and in other laboratory or 
livestock animal species [17, 19] are believed to be markers for the expression of different 
P450 forms (CYPs), based on molecular models of mammalian enzymes [20]. Thus, 
oleandomycin triacetate and erythromycin were selected as CYP3A substrates, whilst 
aminopyrine and chlorfeniramine were markers of CYP2C-mediated activity. All enzyme 
activities were determined by aerobic incubations under conditions yielding zero order rates 
with respect to cofactor and substrate concentrations and ensuring linearity with respect to 
time and protein concentrations. Oxidative P450-dependent N-demethylation activities toward 
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oleandomycin triacetate (0.3 mM), erythromycin (1 mM), aminopyrine (5 mM) and 
chlorfeniramine (1mM) were assayed using the NADPH-generating system and 1 mg of 
microsomal protein. After a suitable incubation time, reactions were quenched with chilled 
trichloroacetic acid (10 %, w/v) and, after centrifugation, the amount of the released 
formaldehyde was determined fluorometrically on an aliquot of the clear supernatant with 
Nash’s reagent as detailed by Werringloer, (1978) [21]. Incubations of the same substrates 
with liver microsomes from untreated rats were used as controls.  
 
2.7. Incubation assays with sheep ruminal fluid: Aliquots (1.96 mL) of sheep ruminal fluid 
were incubated under anaerobic conditions with 40 µM of FLBZ or red-FLBZ during 15, 30 and 
60 min following previously described procedures [12]. Incubations containing 40 µM of 
ABZSO were used as positive controls since this molecule is extensively reduced by the ruminal 
fluid under in vitro conditions [22].  
 
2.8. Drug/metabolites extraction: Twenty (20) µL of the internal standard (IS) ABZSO (250 
nmol/mL) were added to the inactivated microsomal or cytosolic incubation mixture. Then, 
samples were mixed with 2 mL acetonitrile, vortexed during 20 min and centrifuged at 4000 g 
for 15 min at 10 °C. The supernatant was recovered and evaporated to dryness using an 
Automatic Environmental Speed Vac System (Savant, Holbrook, USA). The dry residue was re-
dissolved in 40 % acetonitrile in water and 50 µL were injected into the HPLC system. 
 
Drug/metabolites physico-chemical extraction from ruminal fluid samples was performed 
following previously reported procedures [12].  
 
Page 11 of 43
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 11 
2.9. Chromatographic analysis: Samples were analysed for ABZSO (IS), FLBZ, red-FLBZ and 
h-FLBZ by HPLC. Fifty microlitres (50 µL) of each extracted sample were injected through an 
autosampler (Shimadzu SIL-10 A Automatic Sample Injector) into a Shimadzu 10 A HPLC 
system (Shimadzu Corporation, Kyoto, Japan) fitted with a Selectosil C18 (5 µm, 250 mm x 4.60 
mm) reverse-phase column (Phenomenex, CA, USA) and UV detector (Shimadzu, SPD-10A 
UV detector) reading at 292 nm. The mobile phase was (40/60) acetonitrile/ammonium acetate 
(0.025 M, pH 5.3). The analytes were identified with the retention times of pure reference 
standards. Chromatographic peak areas of the analytes were measured using the integrator 
software (LCsolution, Shimadzu Corporation, Kyoto, Japan) of the HPLC system.  
 
The red-FLBZ chromatographic peak fractions were collected into a glass tube by using a 
fraction collector (FRC-10A Shimadzu Corporation, Kyoto, Japan). The collected fractions 
were evaporated to dryness and redissolved with 10 % 2–propanol in water. Fifty microlitres (50 
µL) of each sample were injected into the HPLC system fitted with a chiral stationary phase 
column (5 µm, 100 mm x 4.0 mm) (Chiral-AGP column, ChromTech, Hägersten, Sweden). This 
chiral chromatographic method was adapted from a methodology described previously for the 
chiral separation of ABZSO [23]. Reduced FLBZ enantiomers were identified after the 
chromatographic analysis of a pure racemic standard of each molecule. The relative proportions 
(%) of each antipode were obtained using the integrator software of the HPLC system.  
 
2.10. Drugs/metabolites quantification: Validation of the analytical procedures for extraction 
and quantification of FLBZ and their metabolites was performed before starting the analysis of 
the experimental samples from the incubation trials. Known amounts of each analyte (2-60 
nmol/mL) were added to aliquots of boiled (inactivated) microsomal preparations and ruminal 
fluid samples. The fortified samples were extracted and analysed by HPLC (triplicate 
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determinations) to obtain calibration curves and percentages of recovery. Calibration curves were 
prepared using the least squares linear regression analysis (Instat 3.00, Graph Pad Software, 
Inc., San Diego, USA) of HPLC peak area ratios of analytes/internal standard and nominal 
concentrations of spiked samples. A lack-of-fit test was also carried out to confirm the linearity 
of the regression line of each analyte. The concentrations in the experimental samples were 
determined following interpolation of peak area ratios of analytes/internal standard into the 
standard curves. Absolute recoveries were established by comparison of the detector responses 
(peak areas) obtained for spiked microsomal samples (5, 10 and 20 nmol/mL) and those of direct 
standards prepared in mobile phase. The correlation coefficients, percentages of recovery, 
precision and accuracy values determined for FLBZ and red-FLBZ in liver microsomes and 
ruminal fluid are summarized in Table 1. 
 
2.11. Data and statistical analysis: The reported data are expressed as mean ± SD. Metabolic 
rates are expressed in nmol of metabolic products formed per min.mg of microsomal or 
cytosolic protein (nmol/min.mg). Statistical comparisons were carried out using the Instat 
3.00 software (Graph Pad Software, Inc., San Diego, USA). Metabolic rates were compared 
using Student t-test except for inhibition experiments of FLBZ metabolism were ANOVA 
was the selected statistical t st. A value of P<0.05 was considered statistically significant.  
 
3. Results 
 
3.1. Characterization of CBR activities in liver and duodenal subcellular fractions: The 
time-dependent oxidation of NADPH was monitored fluorometrically using MEN as a 
specific CBR substrate. The Eadie-Hofstee plot of CBR activity in sheep liver microsomes 
and the mean Km and Vmax values of the metabolic reaction are shown in Figure 2. The 
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enzyme contained in the liver microsomal fraction shows typical one-site Michaelis–Menten 
kinetics. The Km and Vmax values ranged from 131.7 to 268 µM and 68.26 to 80.95 
nmol/min.mg, respectively. Quercetin (20 µM) inhibited (35.7 %) the CBR-mediated 
microsomal keto-reduction of 125 µM MEN (Figure 2) in sheep liver.  
 
The CBR-mediated activity in microsomal and cytosolic fractions obtained from sheep liver 
and duodenal mucosa is shown in Table 2. Hepatic metabolic activities were 4.3-fold 
(microsomes) and 3.4-fold (cytosolic fraction) higher (P<0.05) than those measured in the 
duodenal mucosa.  
 
3.2. Hepatic and extra-hepatic biotransformation of FLBZ: The viability and metabolic 
capacity of the ruminal microflora was corroborated following the incubation of ABZSO 
under anaerobic conditions. These metabolic assays were used as positive controls, where 
ruminal fluid was able to sulphoreduce ABZSO into ABZ. After 60 min incubation, the 
amount of ABZ formed represented 54.6 ± 6.18 % of the total analytes recovered from the 
incubation mixture. Both FLBZ and red-FLBZ were metabolically stable in ruminal content 
under the same incubation conditions. No metabolic conversion and/or chemical degradation 
were observed following FLBZ or red-FLBZ incubation with sheep ruminal fluid (Figure 3).  
 
Flubendazole (40 µM) was incubated (30 min at 37° C) with the cytosolic and microsomal 
fractions obtained from sheep liver and duodenal mucosa. Both subcellular fractions of each 
tissue were capable to convert FLBZ into red-FLBZ (Figure 4). The production of the FLBZ 
hydrolysed metabolite (h-FLBZ) was not observed under these experimental conditions. The 
amount of red-FLBZ production ranged from 4 to 12.7 nmol/mg (liver microsomes) and 6.86 
to 14.6 nmol/mg (liver cytosolic fraction). The amounts of red-FLBZ formed in liver 
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subcellular fractions were 3-fold (microsomes) and 4-fold (cytosolic fraction) higher (P<0.05) 
compared to that observed in duodenal subcellular fractions. This observation is consistent 
with the higher CBR activities measured in the liver compared to those observed in the gut 
mucosal tissue (see Table 2).  
 
Representative chromatograms obtained following the chiral chromatographic analysis of red-
FLBZ are shown in Figure 5. Two enantiomeric forms were detected after the 
chromatographic analysis of a racemic standard of red-FLBZ (Figure 5A). The keto-reduction 
of the pro-chiral FLBZ led to the prevalent (~98%) stereospecific production of one red-
FLBZ enantiomeric form (RT = 7.4 – 7.6 min) in both liver subcellular fractions (Figure 5B 
and 5C).  
 
Sheep liver microsomes failed to oxidise red-FLBZ into FLBZ in the presence of NADPH. 
However, a NADPH-dependent oxidation produced FLBZ (0.40 ± 0.09 nmol/mg protein) 
from red-FLBZ in rat liver microsomes. Therefore, characterization of the enzymatic pathway 
involved on red-FLBZ oxidation was performed in rat liver microsomes. The effect of PB 
chronic administration on CYP2C and CYP3A-mediated N-demethylase activities measured 
in rat liver microsomes are shown in Table 3. These metabolic activities were 2.3 to 3.6-fold 
higher in PB-induced compared to control rats. Consistently, red-FLBZ oxidation to FLBZ 
resulted 8.6-fold higher in PB-induced compared to control liver microsomes, while this 
metabolic reaction was inhibited (84 %) in the presence of PBO (Table 4).  
 
3.3. Modulation of FLBZ keto-reduction in the liver: The effects of MEN, WRF, MBZ and 
PBO on the liver microsomal keto-reduction of FLBZ are shown in Figure 6. The presence of 
40 µM MEN in the incubation medium led to a 33.3 % inhibition of FLBZ keto-reduction 
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compared to control assays. Higher concentrations of MEN seem to enhance the inhibitory 
effect. WRF did not inhibit the production of red-FLBZ. A significant inhibition of FLBZ 
reduction was also observed in the presence of 160 µM MBZ (46.8 %) and 100 and 200 µM 
PBO (56.1 – 57.7 %, respectively).  
 
4. Discussion 
 
The BZD anthelmintics require extensive hepatic oxidative metabolism to achieve sufficient 
polarity for excretion [24]. Their metabolic pattern and the resultant pharmacokinetic 
behavior are relevant in the attainment of high and sustained concentrations of 
pharmacologically active drug/metabolites at the target parasite [25]. An integrated assessment 
of the pharmacological properties of FLBZ and its potential development for use in sheep was 
previously undertaken in our laboratory [15]. A detailed follow up study addressed to identify 
the metabolic pathways implicated on the extensive FLBZ metabolism in sheep is described 
here.  
 
The metabolic fate of FLBZ was studied in microsomal and cytosolic subcellular fractions 
obtained from liver and duodenal mucosa of adult male sheep. Both subcellular fractions were 
able to convert FLBZ into red-FLBZ. Similarly, the keto-reduction of FLBZ led to the 
production of the reduced metabolite in both cytosolic and microsomal fractions obtained 
from liver tissue and intestinal mucosa of pigs and pheasants [14]. Following FLBZ 
administration to sheep, red-FLBZ was the main metabolite found in the systemic circulation. 
An efficient first-pass metabolism of FLBZ after its gastrointestinal absorption accounted for 
the early detection of red-FLBZ in the bloodstream [15]. The results presented here confirm that 
FLBZ reduction both in the duodenal mucosa and in the liver parenchyma contribute to the 
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observed pre-systemic metabolism of FLBZ. Conversely, ruminal fluid failed to reduce FLBZ, 
which discards the involvement of the rumen microflora as a source of red-FLBZ prior to its 
gastrointestinal absorption (see Figure 3). This finding is opposed to that shown for other 
sulphur-containing BZD anthelmintics, such as albendazole sulphoxide and oxfendazole, which 
are sulphoreduced to their respective thioethers in the rumen [22, 26].  
 
CBRs belong to a class of oxidoreductase proteins enclosed within the family of short chain 
dehydrogenases/reductases. They are ubiquitous in nature and catalyse the NADPH-mediated 
reduction of a large number of biologically and pharmacologically active substrates, including 
a variety of endogenous and xenobiotic carbonyl compounds. Generally, CBRs reduce 
aldehyde and ketone groups of many endo- and xenobiotics such as prostaglandins, steroids, 
biogenic amines, and quinones [27]. Considering that CBRs mediate the reduction of many 
compounds with a ketone group (including FLBZ), this enzymatic activity in both liver and 
duodenal mucosa from sheep was characterised here. The rate of NADPH oxidation in the 
presence of the substrate MEN is a good marker of CBR activity [28]. Both cytosolic and 
microsomal fractions obtained from sheep liver and duodenal mucosa showed CBR-mediated 
reduction of MEN. A typical Michaelis–Menten kinetics characterised the CBR activity in the 
hepatic microsomal fraction (see Figure 2). In addition, metabolic activities measured in liver 
subcellular fractions were 3.4 to 4.3-fold higher compared to those observed in duodenal 
mucosa subcellular fractions (see Table 2). These results are in agreement with a 3 to 4-fold 
higher metabolic reduction of FLBZ in the liver compared to the gut mucosal tissue (see 
Figure 4). A higher ability for FLBZ reduction was previously observed in the liver compared 
to the small intestine in both pigs and pheasants [14]. Altogether these observations may 
indicate that CBR-mediated reduction is the major pathway involved in FLBZ 
biotransformation in these animal species.   
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Enantioselectivity of metabolic products occurs when chiral metabolites are generated 
differentially (in qualitative or quantitative terms) from a single achiral compound through the 
activity of any xenobiotic metabolising enzyme [29]. The CBR-mediated reduction of 
haloperidol led to the predominant production of S(-) reduced haloperidol in human liver and 
brain microsomes, which was also the main enantiomer recovered in urine [30]. Similarly, 
product enantioselectivity was also described for the CBR-mediated reduction of 
propiophenone in rats and rabbits, and idarubicin in various animal species and humans [31, 
32]. The current work showed that the reduction of FLBZ led to the predominant 
stereospecific production of one enantiomeric form of red-FLBZ in liver subcellular fractions, 
which had the largest retention time during the chiral chromatographic analysis (see Figure 5). 
Unfortunately, the analytical methodology necessary to discriminate between both red-FLBZ 
enantiomers is not currently available in our laboratory. However, the (+) red-FLBZ was 
characterised as the main enantiomeric form produced from FLBZ in pigs [14]. Based on 
these observations made in pigs, a close phylogenetical-related species (artiodactyla order), it 
is possible to speculate that metabolic activity of liver CBRs may produced the (+) red-FLBZ 
in sheep.  
 
As it was explained above, red-FLBZ is the main metabolic product formed from FLBZ both 
in vitro and in vivo. Conversely, the hydrolysis of FLBZ was not observed under these 
experimental conditions in both liver and intestinal subcellular fractions. In addition, this 
metabolic reaction did not occur following FLBZ nor red-FLBZ incubation with sheep 
ruminal fluid. Many other tissues of minor relevance for xenobiotic metabolism, such as 
blood, lung parenchyma and kidneys, may be involved in the hydrolysis of FLBZ in vivo, 
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which could account for the detection of traces of h-FLBZ in the systemic circulation of 
FLBZ-treated sheep [15]. 
 
Reduced metabolites formed in a CBR-mediated reaction may be oxidised back to their 
precursor by the P450 enzymatic system. For instance, it has been shown that reduced 
haloperidol is oxidised to haloperidol by CYP2D6 and other P450 isoforms in human liver 
microsomes [33]. Based in such observation, it was hypothesised that the P450 system is 
involved on red-FLBZ oxidation in sheep liver. However, sheep liver microsomes failed to 
convert red-FLBZ into FLBZ in the presence of NADPH. Conversely, a NADPH-dependent 
oxidation of red-FLBZ was observed in rat liver microsomes. Thus, complementary assays 
were carried out to establish whether the P450 system is involved in red-FLBZ oxidation in 
rat liver. PB is a well–known inducer of several P450 isoforms, including CYP2B, 2C and 3A 
[34]. Thus, more than 2.3-fold increments on CYP2C and CYP3A-mediated metabolic 
activities were observed in the liver of PB-induced rats (see Table 3). These findings agree 
with previous reported data showing that PB induced the expression and the activities of these 
P450 isoforms [34 - 36]. In addition to the observed P450 induction, the oxidation of red-
FLBZ to FLBZ resulted 8.6-fold higher in PB-induced compared to control rat liver 
microsomes. Piperonyl butoxide, a well known P450 inhibitor, decreased (84 %) red-FLBZ 
oxidation in liver microsomes from PB-induced rats. Although this oxidative pathway for red-
FLBZ is absent in sheep liver, the observations obtained in the rat after both induction and 
inhibition experiments, may confirm the involvement of the P450 system in this metabolic 
reaction.  
 
Interference with the liver oxidative metabolism has resulted in pronounced modifications to 
the pharmacokinetic behaviour of BZD parent drugs or their active metabolites. It has been 
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shown that co-administration of sulphur-containing BZDs with known FMO [37] or P450 [38, 
39] metabolic inhibitors enhance the plasma availabilities of the parent drug or its 
metabolites. The higher plasma levels of anthelmintically active molecules may prolong the 
plasma-tissue recycling process and increase their concentrations at the most important tissues 
of parasite location [25], which may improve the clinical efficacy of the administered 
compound as a result of higher levels of active drug/metabolites being presented to the 
parasite for longer periods of time. It is well known that biotransformation of BZD 
anthelmintics leads to more polar and less active metabolites. In fact, in terms of parasite 
uptake [40, 41] and mode of action (binding to nematode tubulin) [42], the parent drugs (such 
as FLBZ) are more efficient than their respective metabolites. Although there is not 
information available on the anthelmintic activity of red-FLBZ, this metabolite is supposed to 
be less potent (or may be inactive) compared to the parent drug. Therefore, CBR-mediated 
FLBZ metabolism may give rise to a considerable reduction on its anthelmintic efficacy. 
Among the CBR substrates tested, MEN and MBZ inhibited FLBZ keto-reduction in sheep 
liver microsomes (see Figure 7), which may also confirm the involvement of this enzymatic 
system on the production of red-FLBZ in sheep liver. Although PBO is known as a P450 
inhibitor, this compound also reduced the formation of red-FLBZ. This finding may indicate 
that CBRs are also target enzymes for PBO. Interestingly, other enzymes such as non-specific 
esterases are also inhibited by PBO [43]. It is important to emphasise that this metabolic 
inhibitor is widely used to improve the efficacy of some ectoparasiticide compounds such as 
pyrethroids and rotenone [44, 45]. Despite of the selected inhibitor, the modulation of FLBZ 
metabolism under in vivo conditions should be considered as a useful tool to improve its 
systemic availability and clinical anthelmintic efficacy in sheep as well as in other livestock 
species. 
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In conclusion, the hepatic and extra-hepatic metabolic fate of FLBZ in sheep was 
characterised in this work for the first time. CBR activities measured in liver microsomal and 
cytosolic fractions were higher compared to those observed in both subcellular fractions 
obtained from the duodenal mucosa. This finding correlates with the higher FLBZ ketone-
reduction observed in the liver compared to the small intestinal mucosa. The reduction of 
FLBZ in sheep liver was enantioselective, presumably to the (+) red-FLBZ. While the P450-
mediated oxidation of red-FLBZ into FLBZ was observed in rat liver microsomes, this 
metabolic pathway is absent in sheep liver. MEN, MBZ and PBO inhibited FLBZ reduction in 
sheep liver microsomes. These metabolic interferences observed in vitro should be considered 
as a useful tool to improve FLBZ systemic availability and efficacy. The research reported 
here is a further contribution to the understanding of the metabolic fate of a promissory 
anthelmintic drug to be used for parasite control in ruminants. Regardless the relevance of the 
specific drug substrate investigated here, the metabolic approach followed in this work is 
useful to be applied to assess the unknown pattern of biotransformation for a large number of 
xenobiotic compounds of pharmaco-toxicological relevance. 
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Table 1: Validation parameters determined for the chromatographic analysis of flubendazole 
(FLBZ) and its reduced metabolite (red-FLBZ) in liver microsomes and ruminal fluid. 
 
 Liver microsomes Ruminal fluid 
Validation 
parameters FLBZ red-FLBZ FLBZ red-FLBZ 
r 0.999 0.998 0.999 0.999 
Recovery (%) 80.5-89.7 79.7-84.5 93.6-99.9 92.2-98.2 
Precision (CV) 1.58-6.61 2.69-8.11 5.21-8.30 3.47-9.10 
Accuracy (%) 0.15-8.10 0.10-9.59 0.39-11.0 0.09-11.8 
 
Calibration curves were prepared by processing inactivated microsomal and rumianl fluid 
samples fortified with each analyte (3 replicates for each concentration). Recovery, precision 
and accuracy were evaluated by processing replicates (n = 4) of FLBZ and red-FLBZ in each 
biological sample at 5, 10 y 20 nmol/mL. r, correlation coefficient; CV, coefficient of 
variation.  
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Table 2: Carbonyl reductase (CBR) activities measured in microsomal and cytosolic fractions 
obtained from sheep liver and duodenal mucosa.  
 
 Liver  Duodenal mucosa  
 Microsomal 
fraction 
Cytosolic 
fraction 
Microsomal 
fraction 
Cytosolic 
fraction 
CBR activity 
(nmol/min.mg) 52.8 ± 4.62 (*) 39.9 ± 9.44 (*) 12.1 ± 2.09 11.7 ± 3.94 
 
Metabolic activities (nmol/min.mg of protein) were measured using menadione (500 µM) as a 
substrate and monitoring the oxidation rate of NADPH (see Materials and Methods). Data are 
expressed as mean ± SD (n = 5 animals). (*): Mean values are significantly different (P<0.05) 
compared to those measured in the same subcellular fraction from the duodenal mucosa.  
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Table 3: Comparative N-demethylase activities measured in liver microsomes obtained from 
control and phenobarbital (PB) induced rats.  
 
CYP subfamily    Enzyme activity Control  PB-induced 
2C aminopyrine             
N-demethylase 
11.6 ± 1.92 27.0 ± 4.30               
(P = 0.001) 
2C chlorpheniramine  
N-demethylase 
6.22 ± 2.34 15.7 ± 4.46               
(P = 0.009) 
3A oleandomycin-triacetate                      
N-demethylase 
0.98 ± 0.36 3.51 ± 1.09                
(P = 0.020) 
3A erythromycin           
N-demethylase 
0.92 ± 0.45 2.12 ± 1.17               
(P = 0.106) 
 
Enzymatic activities (mean ± SD) are expressed in nmol of formaldehyde released per 
min.mg of microsomal protein (n = 4 animals). P values obtained after the statistical 
comparison (Student t-test) between both experimental groups are shown in brackets.  
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Table 4: In vitro oxidation of reduced flubendazole (red-FLBZ) into flubendazole (FLBZ) by 
control and phenobarbital (PB) induced rat liver microsomes. 
 
 
 PB-induced microsomes a 
 Control 
microsomes 
PB-induced 
microsomes 
Control  
incubations 
Incubations with 
PBO 100 µM 
FLBZ % 100 861 ± 315 (**) 100 15.8 ± 7.41 (**) 
 
a
 Effect of the cytochrome P450 inhibitor, piperonyl butoxide (PBO), on red-FLBZ oxidation 
by PB-induced rat liver microsomes. Mean ± SD values (n = 4 animals) are expressed as 
percentage of FLBZ formed with respect to their respective controls (equal to 100 %).   
(*): Significantly different (P<0.01) compared to control.  
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Figure legends 
 
 
Fig. 1. Proposed pattern of flubendazole (FLBZ) biotransformation.  
 
 
Fig. 2. Eadie-Hofstee plot and Michaelis-Menten constants of carbonyl reductase (CBR) 
activity in ovine liver microsomes. The inhibitory effect of quercetin is shown in the inserted 
table. Km (µM): substrate concentration giving half-maximal velocity. Vmax (nmol/min.mg): 
maximal velocity of the metabolic reaction. Data are expressed as mean ± SD (n = 5 animals). 
(*): The mean value is significantly different (P<0.05) compared to that obtained in control 
incubations without quercetin.  
 
 
Fig. 3. Metabolic stability of flubendazole (FLBZ) and reduced flubendazole (red-FLBZ) 
observed after their incubation (between 15 and 60 min) with sheep ruminal fluid under 
anaerobic conditions. The results are expressed as the percentage of unchanged parent drug 
recovered from the incubation medium compared with those determined in metabolically 
inactive (boiled) ruminal fluid (control incubations). Data (mean ± SD) were obtained 
following FLBZ or red-FLBZ incubations with ruminal fluid obtained from 3 animals. The 
insert shows typical chromatograms obtained following the analysis of unfortified (blank) 
ruminal fluid sample (left panel), FLBZ-added (inactivated) ruminal fluid sample (middle 
panel) and FLBZ incubated in experimental metabolically active ruminal fluid (right panel).  
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Fig. 4. Comparative biotransformation of flubendazole (FLBZ) by microsomal and cytosolic 
fractions obtained from sheep liver and duodenal mucosa. The initial FLBZ concentration was 
40 µM. Data (mean ± SD) are expressed in nmol of red-FLBZ per mg of microsomal or 
cytosolic protein (n = 4 animals). (*): Mean values are significantly different (P<0.05) 
compared to those obtained in the same subcellular fraction from the duodenal mucosa.  
 
 
Fig. 5. Representative chromatograms obtained after the chiral chromatographic analysis of a 
racemic standard of reduced flubendazole (red-FLBZ) (A) and experimental samples obtained 
after the incubation of flubendazole (FLBZ) with sheep liver cytosolic (B) and microsomal 
(C) fractions. 
 
 
Fig. 6. Effects of menadione (MEN), warfarin (WRF), mebendazole (MBZ) and piperonyl 
butoxide (PBO) on the biotransformation of flubendazole (FLBZ) by sheep liver microsomes. 
The initial FLBZ concentration was 40 µM. Data (mean ± SD) are expressed in nmol of red-
FLBZ formed per min per mg of microsomal protein (n = 5 animals). Mean values are 
significantly different from control incubations at (*) P<0.05 and (**) P<0.01.  
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Table 1: Validation parameters determined for the chromatographic analysis of 
flubendazole (FLBZ) and its reduced metabolite (red-FLBZ) in liver microsomes and 
ruminal fluid.
Liver microsomes Ruminal fluid
Validation 
parameters
FLBZ red-FLBZ FLBZ red-FLBZ
r 0.999 0.998 0.999 0.999
Recovery (%) 80.5-89.7 79.7-84.5 93.6-99.9 92.2-98.2
Precision (CV) 1.58-6.61 2.69-8.11 5.21-8.30 3.47-9.10
Accuracy (%) 0.15-8.10 0.10-9.59 0.39-11.0 0.09-11.8
Calibration curves were prepared by processing inactivated microsomal and rumianl 
fluid samples fortified with each analyte (3 replicates for each concentration). Recovery, 
precision and accuracy were evaluated by processing replicates (n = 4) of FLBZ and 
red-FLBZ in each biological sample at 5, 10 y 20 nmol/mL. r, correlation coefficient; 
CV, coefficient of variation. 
Table
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Table 2: Carbonyl reductase (CBR) activities measured in microsomal and cytosolic 
fractions obtained from sheep liver and duodenal mucosa. 
Liver Duodenal mucosa 
Microsomal 
fraction
Cytosolic 
fraction
Microsomal 
fraction
Cytosolic 
fraction
CBR activity 
(nmol/min.mg)
52.8 ± 4.62 (*) 39.9 ± 9.44 (*) 12.1 ± 2.09 11.7 ± 3.94
Metabolic activities (nmol/min.mg of protein) were measured using menadione (500 
M) as a substrate and monitoring the oxidation rate of NADPH (see Materials and 
Methods). Data are expressed as mean ± SD (n = 5 animals). (*): Mean values are 
significantly different (P<0.05) compared to those measured in the same subcellular 
fraction from the duodenal mucosa. 
Table
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Table 3: Comparative N-demethylase activities measured in liver microsomes obtained 
from control and phenobarbital (PB) induced rats. 
CYP subfamily   Enzyme activity Control PB-induced
2C aminopyrine            
N-demethylase
11.6 ± 1.92 27.0 ± 4.30               
(P = 0.001)
2C chlorpheniramine 
N-demethylase
6.22 ± 2.34 15.7 ± 4.46               
(P = 0.009)
3A oleandomycin-triacetate                      
N-demethylase
0.98 ± 0.36 3.51 ± 1.09                
(P = 0.020)
3A erythromycin          
N-demethylase
0.92 ± 0.45 2.12 ± 1.17               
(P = 0.106)
Enzymatic activities (mean ± SD) are expressed in nmol of formaldehyde released per 
min.mg of microsomal protein (n = 4 animals). P values obtained after the statistical 
comparison (Student t-test) between both experimental groups are shown in brackets. 
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Table 4: In vitro oxidation of reduced flubendazole (red-FLBZ) into flubendazole 
(FLBZ) by control and phenobarbital (PB) induced rat liver microsomes.
PB-induced microsomes a
Control 
microsomes
PB-induced 
microsomes
Control 
incubations
Incubations with 
PBO 100 M
FLBZ % 100 861 ± 315 (**) 100 15.8 ± 7.41 (**)
a Effect of the cytochrome P450 inhibitor, piperonyl butoxide (PBO), on red-FLBZ 
oxidation by PB-induced rat liver microsomes. Mean ± SD values (n = 4 animals) are 
expressed as percentage of FLBZ formed with respect to their respective controls (equal 
to 100 %).  
(*): Significantly different (P<0.01) compared to control. 
Table
